Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (111-120 of 182) with videos related to

Pageof 19
Sort By:
Brain Communications|July 30, 2024
Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosisElisa Colato, Jonathan Stutters, Sridar Narayanan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 20, 2023
Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson's diseaseNaomi Hannaway, Angeliki Zarkali, Louise-Ann Leyland, et al.
Practical Neurology|June 24, 2015
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosisNeil Scolding, David Barnes, Sarah Cader, et al.
BMJ Neurology Open|June 3, 2021
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosisKushan Karunaratne, Dariush Ahrabian, Bernadette Monoghan, et al.
European Journal of Neurology|July 9, 2025
Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 CohortCharles Wade, Anisha Doshi, Sean Apap Mangion, et al.
Multiple Sclerosis and Related Disorders|February 8, 2025
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MSAnisha Doshi, Nils Muhlert, Gloria Castellazzi, et al.
Neurobiology of Aging|July 13, 2010
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutationsCoro Paisán-Ruiz, Abi Li, Susanne A Schneider, et al.
The Patient|April 18, 2023
Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World ChoicesEdward J D Webb, David Meads, Ieva Eskytė, et al.
The Patient|June 27, 2020
The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying TreatmentsEdward J D Webb, David Meads, Ieva Eskytė, et al.
Plos One|April 10, 2015
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosisHanna M Vesterinen, Peter Connick, Cadi M J Irvine, et al.
Pageof 19

Showing results (111-120 of 182) with videos related to

Sort By:
Pageof 19
Brain Communications|July 30, 2024
Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosisElisa Colato, Jonathan Stutters, Sridar Narayanan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 20, 2023
Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson's diseaseNaomi Hannaway, Angeliki Zarkali, Louise-Ann Leyland, et al.
Practical Neurology|June 24, 2015
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosisNeil Scolding, David Barnes, Sarah Cader, et al.
BMJ Neurology Open|June 3, 2021
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosisKushan Karunaratne, Dariush Ahrabian, Bernadette Monoghan, et al.
European Journal of Neurology|July 9, 2025
Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 CohortCharles Wade, Anisha Doshi, Sean Apap Mangion, et al.
Multiple Sclerosis and Related Disorders|February 8, 2025
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MSAnisha Doshi, Nils Muhlert, Gloria Castellazzi, et al.
Neurobiology of Aging|July 13, 2010
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutationsCoro Paisán-Ruiz, Abi Li, Susanne A Schneider, et al.
The Patient|April 18, 2023
Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World ChoicesEdward J D Webb, David Meads, Ieva Eskytė, et al.
The Patient|June 27, 2020
The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying TreatmentsEdward J D Webb, David Meads, Ieva Eskytė, et al.
Plos One|April 10, 2015
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosisHanna M Vesterinen, Peter Connick, Cadi M J Irvine, et al.
Pageof 19